Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd (TORNTPHARM) is scheduled to report results on 23 Oct 2026. Torrent Pharmaceuticals Ltd last reported results for the quarter ended Jun 2026, with sales of ₹4,921 crore and net profit of ₹566 crore. The stock last traded at ₹4,657, a market capitalisation of ₹1,74,940 crore, on a P/E of 78.4. Over the past 52 weeks the stock has ranged between ₹3,480 and ₹5,250. Figures are as of 9 Oct 2026 and are not real time.
Torrent Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹4,657
- Market cap
- ₹1,74,940 cr
- Stock P/E
- 78.4
- Book value
- ₹248
- ROE
- 27.4%
- ROCE
- 15.2%
- Dividend yield
- 0.82%
- 52w high / low
- 5250/3480
Metrics as of 9 Oct 2026. Not real time.
Track Torrent Pharmaceuticals Ltd
Cruxal reads every Torrent Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Torrent Pharmaceuticals Ltd growth and returns
- 10 Years
- 8%
- 5 Years
- 12%
- 3 Years
- 13%
- TTM
- 33%
- 10 Years
- 2%
- 5 Years
- 12%
- 3 Years
- 22%
- TTM
- 10%
- 10 Years
- 19%
- 5 Years
- 25%
- 3 Years
- 36%
- 1 Year
- 31%
- 10 Years
- 22%
- 5 Years
- 24%
- 3 Years
- 26%
- Last Year
- 27%
Torrent Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹4,921 cr, up 54.8% from ₹3,178 cr a year earlier. Net profit was ₹566 cr, up 3.3% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,889 | 2,809 | 2,959 | 3,178 | 3,302 | 3,303 | 4,197 | 4,921 |
| Expenses | 1,950 | 1,895 | 1,995 | 2,146 | 2,219 | 2,215 | 2,841 | 3,257 |
| Operating profit | 939 | 914 | 964 | 1,032 | 1,083 | 1,088 | 1,356 | 1,664 |
| OPM % | 32% | 33% | 33% | 32% | 33% | 33% | 32% | 34% |
| Other income | -16 | 33 | -42 | -37 | -40 | -23 | -83 | -33 |
| Interest | 64 | 57 | 56 | 56 | 48 | 45 | 236 | 305 |
| Depreciation | 198 | 199 | 201 | 201 | 204 | 206 | 508 | 593 |
| Profit before tax | 661 | 691 | 665 | 738 | 791 | 814 | 529 | 733 |
| Tax % | 31% | 27% | 25% | 26% | 25% | 22% | 31% | 23% |
| Net profit | 453 | 503 | 498 | 548 | 591 | 635 | 364 | 566 |
| EPS (₹) | 13.38 | 14.86 | 14.71 | 16.19 | 17.46 | 18.76 | 10.76 | 16.72 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Torrent Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,816 | 5,950 | 7,673 | 7,939 | 8,005 | 8,508 | 9,620 | 10,728 | 11,516 | 13,980 | 15,723 |
| Operating profit | 1,377 | 1,349 | 1,983 | 2,170 | 2,480 | 2,431 | 2,842 | 3,368 | 3,721 | 4,558 | 5,191 |
| OPM % | 24% | 23% | 26% | 27% | 31% | 29% | 30% | 31% | 32% | 33% | 33% |
| Net profit | 934 | 678 | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,911 | 2,138 | 2,156 |
| EPS (₹) | 27.59 | 20.04 | 12.89 | 30.28 | 36.99 | 22.97 | 36.79 | 48.94 | 56.47 | 63.92 | 63.70 |
TTM is the trailing twelve months to the most recent quarter.
Torrent Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 |
| Reserves | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 6,029 | 6,687 | 7,421 | 8,219 |
| Borrowings | 2,510 | 6,462 | 6,038 | 5,784 | 4,874 | 4,070 | 5,369 | 4,022 | 3,202 | 15,026 |
| Other liabilities | 2,740 | 3,159 | 3,351 | 3,402 | 3,363 | 2,884 | 3,043 | 3,627 | 3,603 | 20,200 |
| Total liabilities | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 | 43,614 |
| Fixed assets | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 8,121 | 8,138 | 7,947 | 33,191 |
| CWIP | 519 | 647 | 617 | 712 | 889 | 630 | 765 | 361 | 478 | 641 |
| Investments | 804 | 492 | 353 | 2 | 181 | 226 | 199 | 173 | 156 | 948 |
| Other assets | 4,589 | 5,249 | 5,395 | 5,763 | 5,940 | 5,628 | 5,524 | 5,834 | 5,815 | 8,833 |
| Total assets | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 | 43,614 |
As reported by the company. Total assets equal total liabilities by construction.
Torrent Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1,009 | 894 | 1,798 | 1,393 | 2,005 | 1,803 | 2,368 | 3,266 | 2,585 | 3,023 |
| Cash from investing | -798 | -4,677 | -246 | 229 | -444 | -196 | -2,335 | -160 | -549 | -12,630 |
| Cash from financing | -193 | 3,417 | -1,314 | -1,549 | -1,651 | -1,781 | 77 | -2,780 | -2,298 | 10,151 |
| Net cash flow | 18 | -366 | 238 | 73 | -89 | -174 | 110 | 327 | -262 | 544 |
| Free cash flow | 523 | 105 | 1,138 | 990 | 1,671 | 1,607 | 1,953 | 2,967 | 1,991 | 2,386 |
| CFO / operating profit | 101% | 87% | 105% | 77% | 88% | 91% | 97% | 112% | 86% | 84% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Torrent Pharmaceuticals Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 19% | 13% | 13% | 15% | 17% | 19% | 20% | 23% | 27% | 15% |
| Debtor days | 60 | 77 | 68 | 76 | 69 | 70 | 74 | 63 | 59 | 79 |
| Inventory days | 318 | 429 | 318 | 362 | 456 | 368 | 298 | 310 | 334 | 338 |
| Days payable | 356 | 447 | 345 | 345 | 351 | 250 | 224 | 284 | 239 | 254 |
| Cash conversion cycle | 21 | 59 | 42 | 93 | 174 | 188 | 147 | 89 | 154 | 163 |
| Working capital days | 28 | -80 | -62 | -52 | -5 | 7 | -33 | -27 | 7 | -26 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Torrent Pharmaceuticals Ltd shareholding pattern
Promoters held 60.78% at Jul 2026, down from 68.31% at Sep 2025. FIIs 17.97% and DIIs 12.77%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 68.31% | 68.31% | 68.31% | 68.31% | 68.31% | 68.31% | 68.31% | 60.78% |
| FIIs | 16.17% | 16.31% | 16.09% | 15.92% | 16.13% | 16.18% | 15.44% | 17.97% |
| DIIs | 8.25% | 8.25% | 8.54% | 9.17% | 9.05% | 8.96% | 9.73% | 12.77% |
| Government | 0.10% | 0.10% | 0.10% | 0.10% | 0.10% | 0.00% | 0.10% | 0.09% |
| Public | 7.17% | 7.02% | 6.93% | 6.47% | 6.41% | 6.55% | 6.42% | 8.39% |
| No. of shareholders | 85,035 | 86,005 | 81,856 | 78,226 | 76,214 | 83,811 | 85,776 | 1,40,599 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Torrent Pharmaceuticals Ltd’s next results date?
Torrent Pharmaceuticals Ltd’s next results are scheduled for 23 Oct 2026.
- Board meetingApproval of financial results for quarter and half-year ended 30-Sep-26
- Earnings resultsQ2 FY2027 financial performance discussion
See the full results calendar for every Indian company reporting in the next 30 days.
Torrent Pharmaceuticals Ltd corporate filings
- Torrent Pharma schedules investor conference call on 23rd October 2026 to discuss Q2 FY24 financialsCompany Updatelow impact
Cruxal's analysis: Torrent Pharmaceuticals has announced a teleconference with investors and analysts…
Read the full analysis - Torrent Pharmaceuticals Receives Credit Rating Upgrade to IND AA+/Positive Outlook from India Ratings, Signaling Improved CreditworthinessCompany Updatehigh impact
Cruxal's analysis: Torrent Pharmaceuticals has been reaffirmed with a credit rating of IND AA+ with a…
Read the full analysis - Torrent Pharmaceuticals Announces Board Meeting to Consider Financial Results for Q2 FY2027 (Quarter ending September 2026)Board Meetingmedium impact
Cruxal's analysis: Torrent Pharmaceuticals has scheduled a board meeting on 23rd October 2026 to approve its…
Read the full analysis - Torrent Pharmaceuticals increases investment in Torrent Urja 27 Private Limited for captive renewable energy projectCompany Updatelow impact
Cruxal's analysis: Torrent Pharmaceuticals Limited has announced an amendment to its Share Subscription and…
Read the full analysis - Intimation of Closure of Trading Window Period - Q2Insider Trading / SASTlow impact
- Torrent Pharmaceuticals schedules investor meets for September 2026Company Updatelow impact
Cruxal's analysis: Torrent Pharmaceuticals has issued an intimation regarding upcoming investor meets. The…
Read the full analysis - Torrent Pharmaceuticals announces newspaper publication for physical share transfer and dematerializationCompany Updatelow impact
Cruxal's analysis: Torrent Pharmaceuticals has published a newspaper advertisement regarding a special…
Read the full analysis - Torrent Pharmaceuticals Limited announces successful appointment of Shanti Ekambaram as Independent Director via postal ballotAGM/EGMlow impact
Cruxal's analysis: Torrent Pharmaceuticals Limited has successfully concluded its postal ballot process…
Read the full analysis - Torrent Pharmaceuticals schedules investor meeting for August 2026Company Updatelow impact
Cruxal's analysis: Torrent Pharmaceuticals has issued an intimation regarding a scheduled investor meeting…
Read the full analysis - Torrent Pharmaceuticals Ltd discloses ESG rating updateCompany Updatelow impact
Cruxal's analysis: Torrent Pharmaceuticals has provided an intimation under Regulation 30 of SEBI (LODR)…
Read the full analysis - Torrent Pharmaceuticals completes dispatch of Postal Ballot NoticeCompany Updatelow impact
Cruxal's analysis: Torrent Pharmaceuticals has completed the dispatch of the Postal Ballot Notice to its…
Read the full analysis - Torrent Pharmaceuticals initiates postal ballot for appointment of Shanti Ekambaram as Independent DirectorAGM/EGMlow impact
Cruxal's analysis: Torrent Pharmaceuticals has issued a notice of postal ballot to seek shareholder approval…
Read the full analysis - Torrent Pharma Discloses Q1 FY27 Earnings Call Transcript for Quarter Ended June 2026Company Updatelow impact
Cruxal's analysis: Torrent Pharmaceuticals Limited has announced the availability of the transcript for its…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.